Trial Profile
A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vigamox in the Treatment of Bacterial Conjunctivitis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2013
Price :
$35
*
At a glance
- Drugs Besifloxacin (Primary) ; Moxifloxacin
- Indications Bacterial infections; Infectious conjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors Bausch & Lomb
- 01 Sep 2009 Results have been published in Ophthalmology.
- 31 Aug 2009 New trial record